American Well (AMWL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors, Dr. Ido Schoenberg and Dr. Roy Schoenberg, to serve until the 2029 annual meeting is proposed, with board recommendation to vote in favor.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, is recommended for approval.
Advisory approval of executive compensation for named executive officers, as detailed in the proxy statement, is recommended by the board.
Board of directors and corporate governance
Two Class III directors are up for election to serve three-year terms, continuing the staggered board structure.
Executive compensation and say-on-pay
Shareholders are asked to approve, on an advisory basis, the compensation of named executive officers as disclosed in the proxy statement.
Latest events from American Well
- Q1 2026 revenue fell 18%, but net loss narrowed and positive cash flow is targeted for Q4.AMWL
Q1 20266 May 2026 - 2025 saw major cost reductions, platform innovation, and strong governance ahead of key shareholder votes.AMWL
Proxy filing23 Apr 2026 - 2026 guidance targets $195–$205M revenue, EBITDA breakeven, and strong government contract momentum.AMWL
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Margins improved and losses narrowed, with positive cash flow targeted for Q4 2026.AMWL
Q4 202512 Feb 2026 - Director elections, auditor ratification, and reverse stock split proposal advanced to vote.AMWL
AGM 20243 Feb 2026 - Q2 revenue rose to $62.8M, losses narrowed, and 2024 EBITDA guidance improved.AMWL
Q2 20242 Feb 2026 - Converge platform drives digital-first care, boosting margins and setting up profitability by 2026.AMWL
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue was $61M, net loss narrowed, and cost actions support 2026 cash flow goals.AMWL
Q3 202417 Jan 2026 - Subscription revenue growth and DHA contract expansion drive confidence in 2026 profitability.AMWL
UBS Global Healthcare Conference14 Jan 2026